January 27, 2026 4:33pm

Risk versus exposure is the crucible as soon to be Q4 and FY25 earnings reporting cycle induces a steamrolling effect

News: Intellia Therapeutics (NTLA +$0.88 or +6.31% to $14.83) FDA Lifts of clinical hold on MAGNITUDE-2 P3 clinical trial in ATTRv-PN. Resuming patient enrollment as quickly as possible

RMi collects, curates, interprets and disseminates cell and gene therapy sector (C&GT) fact-based news, trustable and verified intel of share pricing data bridging the gap to an investment decision

Never leave a retail investor uninformed!  It’s not always time to buy or sell; but it is time to KNOW why!

No Don Quixote as I continually ask, what do all these stock sources, I-Banks and brokers do for you in providing daily information? Availability of data have made intel both complex; I see myself as a collector and my responsibility is to further identify and interpret data to bridge some gaps in an investment decision.

RMi Pre-opening: Don’t step on any cracks in the “random” walks … https://www.regmedinvestors.com/articles/14284

 

I chose to speak-up when many analysts, brokers and commentators have shut-up!

 

Tuesday: The Dow closed DOWN -409.11 points or -0.83%, the S&P closed UP +28.34 points or +0.41% while the Nasdaq closed UP +215.742 points or +0.91%

  • Theme of the session: always awaiting … earnings and Fed policy meeting decision

Tuesday’s (my) 40-company covered sector’s advance/decline line opened positive with 23 incliners, 16 decliners and 1 flat ending with a barely positive close of 21 incliners, 19 decliners and 0 flat

Henry’omics: We need to more than consider the macro-economic environment to comprehend the micro re “our” universe of cell and gene therapy (C&GT) sector

  • The consumer mood in January hit its lowest point in nearly 12 years, according to a Conference Board survey released Tuesday. The index posted a reading of 84.5 for the month, well below the consensus outlook for 90.0. With an upward revision to the December number, the January reading represented a 9.7-point drop to its lowest level since May 2014.
  • Labor conditions also deteriorated. The jobs “plentiful” response was at just 23.9%, down from 27.5% in December, while the “hard to get” response moved up to 20.8% from 19.1%.

The CBOE Fear (VIX) index, Tuesday closed at 16.22, after Monday’s 16.09, after Friday’s 15.92, Thursday’s 15.65, Wednesday’s 16.99 after last Tuesday’s 20.17

Metrics: Tuesday …

  • The RUT was up +7.02 points or +0.26%,
  • The XLV was down -2.65 points or -1.68%,
  • The NBI was up +34.65 points or +0.58%;
  • The XBI was up +0.67 points or +0.52%
  • The IWM was up +0.76 or +0.29%;
  • The IBB was up +1.05 points or +0.60%,
  • The VIX was up +0.07 points or +0.43% at to 16.22

 

Q1/26 – 2 holidays, 2 neutral, 7 negative and 8 positive closes

Q4/25 …

  • December – 1 holiday, 8 positive and 14 negative closes
  • November – 1 holiday, 8 positive and 11 negative closes
  • October -1 neutral, 11 positive and 12 negative closes

 

Tuesday Closing UP (10 of 21) 

  • IQIA Holdings (IQV +$1.73 after Monday’s +$4.12),
  • BioNTech (BNTX +$1.34 after Monday’s +$2.02),
  • Ionis Pharmaceuticals (IONS +$1.14 after Monday’s +$0.76),
  • Intellia Therapeutics (NTLA +$0.88 after Monday’s -$0.68),
  • Mesoblast (MESO +$0-.49 after Monday’s +$0.30),
  • Ultragenyx Pharmaceuticals (RARE +$0.31),
  • Supernus Therapeutics (SUPN +$0.28 after Monday’s +$0.91),
  • Compass Therapeutics (CMPX +$0.22),
  • Agenus (AGEN +$0.17 after Monday’s -$0.22),
  • Cellectis SA (CLLS +$0.12 after Monday’s -$0.385),

Flat (0)

Tuesday’s Closing DOWN (10 of 19): 

  • Alnylam Pharmaceuticals (ALNY -$6.60 after Monday’s +$3.37),
  • Vertex (VRTX -$2.67 after Monday’s +$8.43),
  • Moderna (MRNA -$2.54 after Monday’s -$0.80),
  • Vericel (VCEL -$1.12),
  • uniQure NV (QURE -$0.90),
  • Lenz Therapeutics (LENZ -$0.79 after Monday’s -$0.26),
  • Sarepta Therapeutics (SRPT -$0.59 after Monday’s +$1.63),
  • Regenxbio (RGNX -$0.44),
  • CRISPR Therapeutics (CRSP -$0.39 after Monday’s -$0.87),
  • Beam Therapeutics (BEAM -$0.25 after Monday’s -$0.61)

 

The Bottom Line: More of the … WHY

Indexes closed a mixed, with the S&P 500 reaching an all-time high while the Dow faced downward pressure while the Nasdaq rolled-on.

The reading of consumer confidence dropped to its lowest level since 2014, falling below levels recorded in the depths of the pandemic as Americans face the price effects of an on-again, off-again tariff war and widespread uncertainty over the direction of trade policy.

With a Fed meeting over rates …

A more than real issue facing the economy is a “possible” government shutdown is looming as Senate Democrats attempt to block a bill funding the Department of Homeland Security.

RISK is always a factor remaining below the surface …  boiled-up as slight shocks of profiteering on upsides shook but not rocked the C&GT sector and markets!

  • As I had also written, cash is king for investors who want to keep some liquidity and avoid having to sell into a down market,

 

January – 5th week:

  • 1/27 - Tuesday closed positive with 21 incliners, 19 decliners and 0 flat
  • 1/26 -Monday closed positive with 19 incliners, 18 decliners and 3 flats

January – 4th week:

  • 1/23 – Friday closed negative with 6 incliners, 33 decliners and 1 flat
  • 1/22 – Thursday closed positive with 33 incliners, 6 decliners and 1 flat
  • 1/21 – Wednesday closed positive with 33 incliners, 6 decliners and 1 flat
  • 1/20 - Tuesday closed negative with 16 incliners, 22 decliners and 2 flats
  • 1/19 – Monday was a market holiday, MLK Jr day

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

 

Why do I keep repeating, framed in a different para, so investors can make the connection

The top three (3) performing in the session:    Winners

  • Tuesday: IQIA Holdings (IQV), BioNTech (BNTX) and Ionia Pharmaceuticals (IONS)
  • Monday: Vertex (VRTX), IQIA Holdings (IQV) and Alnylam Pharmaceuticals (ALNY)

The worst three (3) in the session: Losers

  • Tuesday: Alnylam Pharmaceuticals (ALNY), Vertex (VRTX) and Moderna (MRNA)
  • Monday: CRISPR Therapeutics (CRSP), Moderna (MRNA) and Intellia therapeutics (NTLA)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.